We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy.
- Authors
Namba, Mitsuyoshi; Katsuno, Tomoyuki; Kusunoki, Yoshiki; Matsuo, Toshihiro; Miuchi, Masayuki; Miyagawa, Jun-ichiro
- Abstract
Incretin-based therapy was first made available for the treatment of type 2 diabetes mellitus (T2DM) in the US in 2006 and in Japan in 2009. Four DPP-4 inhibitors and two GLP-1 analog/receptor agonists are currently available. The effects of incretin-based therapy are assumed to be exerted mainly through the hormonal and neuronal actions of one of the incretins, GLP-1, which is secreted from L cells localized in the small intestine. The benefits of this therapy over conventional sulfonylureas or insulin injections, such as fewer hypoglycemic events and reduced body weight gain, derive from the glucose-dependent insulinotropic effect. The protective effects of this therapy on vulnerable pancreatic β-cells and against micro/macroangiopathy in T2DM are also most welcome. Indications and/or contraindications for incretin-based therapy should be clarified by prospectively studying the experiences of Japanese T2DM patients undergoing this therapy in the clinical setting.
- Subjects
UNITED States; TYPE 2 diabetes treatment; INCRETINS; GLUCAGON-like peptide-1 receptor; SULFONYLUREAS; BODY weight; PANCREATIC beta cells
- Publication
Clinical & Experimental Nephrology, 2013, Vol 17, Issue 1, p10
- ISSN
1342-1751
- Publication type
Academic Journal
- DOI
10.1007/s10157-012-0709-0